Characterizing Nonarticular Pain at Early Rheumatoid Arthritis Diagnosis: Evolution Over the First Year of Treatment and Impact on Remission in a Prospective Real-World Early Rheumatoid Arthritis Cohort.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      Canadian Early Arthritis Cohort Investigators
    • Publication Information:
      Ahead of Print
    • Source:
      Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Malden, MA : Wiley, [2014]-
    • Abstract:
      Objective: Our objective was to characterize nonarticular pain (NAP) at early rheumatoid arthritis (RA) diagnosis, the evolution over the first year of treatment, associations with active RA inflammation, and the impact on remission.
      Methods: This real-world, longitudinal multicenter cohort study observed participants with active early RA (symptoms <1 year and Clinical Disease Activity Index [CDAI] >2.8) enrolled between January 2017 and January 2022 who completed a body pain diagram over 1 year. Participants were grouped by prespecified definitions of NAP: (1) none, (2) regional, or (3) widespread. Rheumatologists performed joint counts. Descriptive statistics summarized the frequency and evolution of NAP patterns over 1 year. Chi-square tests compared the proportions of tender and/or swollen joints by the presence of pain in each NAP section. Multiadjusted generalized estimating equations regression models estimated associations of NAP patterns with remission outcomes.
      Results: Participants (N = 392) were 70% female, with a mean ± SD age of 56 ± 14 years and mean ± SD symptoms duration of 5.1 ± 2.7 months. More than half reported NAP at baseline, with most (73%) presenting with regional NAP. Common patterns of regional NAP were axial (40%) and pain in upper quadrants (17%). A total of 43% of those with regional NAP persisted or worsened over 1 year, whereas 73% of those with widespread NAP resolved or improved. Joint inflammation was more frequently reported in areas with NAP versus areas without NAP. Regional and widespread NAP were associated with lower odds of reaching CDAI remission (adjusted odds ratio 0.42, 95% confidence interval 0.26-0.70 and adjusted odds ratio 0.30, 95% confidence interval 0.12-0.74), respectively.
      Conclusion: Regional NAP is common and persistent in early RA and impacts remission. RA activity may contribute to NAP. More attention to NAP in RA care is warranted.
      (© 2024 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
    • References:
      Hammer HB, Kvien TK, Terslev L. Tenosynovitis in rheumatoid arthritis patients on biologic treatment: involvement and sensitivity to change compared to joint inflammation. Clin Exp Rheumatol 2017;35(6):959–965.
      Lee YC, Lu B, Boire G, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 2013;72(6):949–954.
      Niemantsverdriet E, van der Helm‐van Mil AHM. Imaging detected tenosynovitis of metacarpophalangeal and wrist joints: an increasingly recognised characteristic of rheumatoid arthritis. Clin Exp Rheumatol 2018;36 Suppl 114(5):131–138.
      Bruyn GA, Moller I, Klauser A, et al. Soft tissue pathology: regional pain syndromes, nerves and ligaments. Rheumatology (Oxford) 2012;51(suppl 7):vii22.
      Donnelly JM. Travell, Simons & Simons’ Myofascial Pain and Dysfunction: The Trigger Point Manual. 3rd ed. Wolters Kluwer; 2019.
      Walker‐Bone KE, Palmer KT, Reading I, et al. Criteria for assessing pain and nonarticular soft‐tissue rheumatic disorders of the neck and upper limb. Semin Arthritis Rheum 2003;33(3):168–184.
      Yamada K, Suzuki A, Takahashi S, et al. MRI evaluation of lumbar endplate and facet erosion in rheumatoid arthritis. J Spinal Disord Tech 2014;27(4):E128–E135.
      Wang WT, Huang SW, Liou TH, et al. Patients with rheumatoid arthritis were associated with a risk of rotator cuff diseases. J Clin Med. 2019;8(2):129.
      Torii M, Hashimoto M, Hanai A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol 2019;29(4):589–595.
      Schelin M, Westerlind H, Lindqvist J, et al. Widespread non‐joint pain in early rheumatoid arthritis. Scand J Rheumatol 2021;50(4):271–279.
      Duffield SJ, Miller N, Zhao S, et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta‐analysis. Rheumatology (Oxford) 2018;57(8):1453–1460.
      Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol 2019;33(3):101423.
      Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46(3):319–329.
      Bykerk VP, Jamal S, Boire G, et al. The Canadian Early Arthritis Cohort (CATCH): patients with new‐onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. J Rheumatol 2012;39(11):2071–2080.
      Bykerk VP, Akhavan P, Hazlewood GS, et al; Canadian Rheumatology Association. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease‐modifying antirheumatic drugs. J Rheumatol 2012;39(8):1559–1582.
      Barber CEH, Schieir O, Lacaille D, et al; Canadian Early Arthritis Cohort Investigators. High adherence to system‐level performance measures for rheumatoid arthritis in a national early arthritis cohort over eight years. Arthritis Care Res (Hoboken) 2018;70(6):842–850.
      Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1(3):277–299.
      Margolis RB, Chibnall JT, Tait RC. Test‐retest reliability of the pain drawing instrument. Pain 1988;33(1):49–51.
      Brummett CM, Bakshi RR, Goesling J, et al. Preliminary validation of the Michigan Body Map. Pain 2016;157(6):1205–1212.
      Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33(2):160–172.
      Mack ME, Hsia E, Aletaha D. Comparative assessment of the different American College of Rheumatology/European League Against Rheumatism Remission definitions for rheumatoid arthritis for their use as clinical trial end points. Arthritis Rheumatol 2017;69(3):518–528.
      Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis 2023;82(1):74–80.
      Hammer HB, Michelsen B, Provan SA, et al. Tender joint count and inflammatory activity in patients with established rheumatoid arthritis: results from a longitudinal study. Arthritis Care Res (Hoboken) 2020;72(1):27–35.
      Mian AN, Chaabo K, Wajed J, et al. Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound. BMC Musculoskelet Disord 2016;17(1):404.
      Chaabo K, Chan E, Garrood T, et al. Pain sensitisation and joint inflammation in patients with active rheumatoid arthritis. RMD Open 2024;10(1):e003784.
      Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30(2):369–378.
      Southerst D, Côté P, Stupar M, et al. The reliability of body pain diagrams in the quantitative measurement of pain distribution and location in patients with musculoskeletal pain: a systematic review. J Manipulative Physiol Ther 2013;36(7):450–459.
      Alter BJ, Anderson NP, Gillman AG, et al. Hierarchical clustering by patient‐reported pain distribution alone identifies distinct chronic pain subgroups differing by pain intensity, quality, and clinical outcomes. PLoS One 2021;16(8):e0254862.
      Scherrer KH, Ziadni MS, Kong JT, et al. Development and validation of the Collaborative Health Outcomes Information Registry body map. Pain Rep 2021;6(1):e880.
      Foxen‐Craft E, Scott EL, Kullgren KA, et al. Pain location and widespread pain in youth with orthopaedic conditions: exploration of the reliability and validity of a body map. Eur J Pain 2019;23(1):57–65.
      Stewart S, Carroll M, Brenton‐Rule A, et al. Region‐specific foot pain and plantar pressure in people with rheumatoid arthritis: a cross‐sectional study. Clin Biomech (Bristol, Avon) 2018;55:14–17.
    • Grant Information:
      Celltrion Healthcare Canada; Jamp Pharma (BIOJAMP); AR080840 NIAMS K24 grant; Pfizer Canada; Hospital for Special Surgery; Viatris Canada; Fresenius Kabi Canada; Sandoz Biopharmaceuticals Canada; Abbvie Corporation
    • Publication Date:
      Date Created: 20241101 Latest Revision: 20241121
    • Publication Date:
      20241122
    • Accession Number:
      10.1002/art.43049
    • Accession Number:
      39482804